SPY366.69-0.10 -0.03%
DIA300.06+0.88 0.29%
IXIC12,377.18+27.82 0.23%

Credit Suisse Maintains Outperform on Stoke Therapeutics, Raises Price Target to $49

Credit Suisse analyst Martin Auster maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $42 to $49.

· 11/13/2020 08:39
Credit Suisse analyst Martin Auster maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $42 to $49.